Engflag

Factor VII

Quick links to important sections

Factor VII

There is no image.

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Factor VII

Property Description
Active ingredient Coagulation Factor VII (Factor VIIa)
Form Lyophilized powder for injection solution
Pharmacological class Hemostatic agent / Blood Coagulation Factor
General purpose Enhancing blood clot formation
Origin Biotechnology-derived (Recombinant DNA) or Plasma-derived

Coagulation Factor VII: Definition and Pharmacological Class

Factor VII, or Coagulation Factor VII, is a highly specialized therapeutic protein classified as a hemostatic agent—a drug used to stop or prevent bleeding. It is inherently a blood coagulation factor, an essential component of the body's natural clotting system. The substance functions as a potent procoagulant.

Origin, Composition, and Dosage Form

Factor VII is a single active ingredient product commonly administered in its synthetic activated form (Factor VIIa). This active component is a biological product typically manufactured using advanced recombinant DNA technology. This modern production method creates a synthetic replica of the human protein designed to support product consistency and purity.

Factor VII is supplied as a lyophilized powder that is mixed with a sterile liquid to create an aqueous solution for injection. This preparation is formulated for intravenous administration, allowing the clotting factor to be delivered directly into the bloodstream for immediate, systemic effect.

What Is the General Purpose of Factor VII?

The general purpose of Coagulation Factor VII is to rapidly secure hemostasis—the medical process of halting blood flow—by providing a direct mechanism for clot stabilization. Its function is to accelerate the cascade to generate thrombin and fibrin mesh, enhancing the ability of blood to coagulate. Acting as a bypass agent to promote clotting quickly and directly is its core purpose.

Regulatory References

  1. NIH, MedlinePlus on Factor VII

What side effects are possible with Factor VII?

Possible Side Effects and Safety Information

The officially documented safety profile for Coagulation Factor VIIa is primarily defined by the potential for serious adverse reactions related to its function as a potent blood clotting agent. All information presented is based strictly on governmental regulatory documents, such as the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).

Serious and Clinically Significant Adverse Reactions

The most critical safety finding is the risk of serious arterial and venous thrombotic events (blood clots). These events, which may include stroke, deep vein thrombosis, and myocardial infarction, are listed as a major warning. Additionally, hypersensitivity reactions, including potentially life-threatening anaphylaxis, are documented as possible adverse immune events.

Common Adverse Reactions and Systemic Effects

Adverse reactions classified as Common (occurring in 1-10% of patients) in regulatory documents include systemic effects such as headache, fever, and dizziness. Reactions occurring at the injection site, such as infusion-site discomfort or hematoma, are also classified within this frequency band.

Safety Considerations for Specific Populations

Regulatory safety information notes specific populations that may be at an increased risk of thrombosis. This includes patients with a history of atherosclerotic disease, liver disease, and older adults. The risk profile also differs between patient groups; for instance, a higher incidence of thrombotic reactions has been documented in patients with Acquired Hemophilia compared to those with Congenital Hemophilia with Inhibitors.

Safety Restrictions and Limitations

Coagulation Factor VIIa is contraindicated in individuals with known hypersensitivity to the active substance or its components, including trace non-human proteins derived from the manufacturing process. Furthermore, regulatory labels warn of an increased thrombotic risk when Factor VIIa is used concurrently with activated prothrombin complex concentrates (aPCCs) or Coagulation Factor XIII.

Overdose and Emergency Response

Factor VII Overdose and When to Seek Help

Official government regulatory documents define the primary risk of Factor VII overdose as the potential for serious arterial and venous thromboembolic adverse events (blood clotting events). The essential components of the drug's official overdose profile are structured around managing this life-threatening risk.

Documented Overdose Presentations

Overdose Presentation Regulatory Response Focus
Thrombotic Complications Monitoring and Intervention
Coagulation System Activation Dosage adjustment/discontinuation

Accidental administrations up to 800 mu g/kg have been noted, though the officially documented, unstudied cumulative daily dose risk is generally defined as greater than 900 mu g/kg. Specific symptoms of thrombosis in an overdose context are monitored by healthcare professionals.

Required Emergency Actions

Immediate medical attention is necessary if a patient experiences any signs or symptoms of thrombosis or severe coagulation system activation. Official regulatory instructions for healthcare providers emphasize continuous monitoring for signs of clotting and prompt action to reduce the dosage or discontinue therapy if thrombosis is suspected or confirmed. Patients with existing risk factors for clotting (such as advanced atherosclerotic disease or sepsis) are noted in official labeling to be at increased risk of these adverse outcomes during potential overdose.

Therapeutic Uses of Factor VII

Main Uses and Benefits of Factor VII

Factor VII is a critical protein in the coagulation cascade, the process by which the body forms blood clots to stop bleeding. Recombinant Factor VIIa is primarily used to manage and prevent bleeding episodes in individuals with specific rare bleeding disorders where standard treatments may be ineffective.

Treatment of Hemophilia with Inhibitors

The primary application of Factor VII is for patients with Hemophilia A or B who have developed inhibitors. Inhibitors are antibodies produced by the immune system that block the effectiveness of traditional factor replacement therapies. Factor VII works by bypassing the steps in the clotting process that require Factor VIII or Factor IX, allowing a clot to form even in the presence of these inhibitors.

Congenital Factor VII Deficiency

This therapy is used as a direct replacement for individuals born with a natural deficiency in Factor VII. Because these patients do not produce enough of the protein themselves, supplemental Factor VII helps restore the blood’s ability to clot during injury or surgery.

Glanzmann’s Thrombasthenia

Factor VII is also utilized for Glanzmann’s thrombasthenia, a rare genetic platelet disorder. In cases where platelet transfusions are no longer effective or available, Factor VII can help stabilize the formation of a fibrin clot at the site of an injury.

Acquired Hemophilia

In some instances, individuals who were not born with a bleeding disorder may suddenly develop antibodies against their own clotting factors. Factor VII is used in these acute situations to manage bleeding until the underlying condition can be addressed.

Key Benefits

  • Bleeding Control: It provides a reliable mechanism to stop active bleeding in complex cases where other clotting factors fail.
  • Surgical Support: It allows patients with rare bleeding disorders to undergo necessary medical and dental procedures by reducing the risk of perioperative hemorrhage.
  • Targeted Action: By specifically activating the extrinsic pathway of coagulation at the site of tissue injury, it helps localize the clotting process.

Regulatory References

  1. European Medicines Agency (EMA) therapeutic overview

Eligibility and Restrictions for Use

Who can and cannot use Coagulation Factor VIIa

The eligibility profile for Coagulation Factor VIIa is defined by regulatory bodies (e.g., FDA, EMA) based on documented indications and specific population restrictions.

Contraindicated and Restricted Populations

Classification Population/Condition
Absolute Contraindication Known severe hypersensitivity or allergy to the active substance, excipients, or specific non-human proteins (e.g., mouse, hamster, bovine, or rabbit proteins) used in manufacturing.
Use with Caution/Restricted Patients with high thrombotic risk, including those with advanced atherosclerotic disease, a history of coronary heart disease, or septicemia.
Use with Caution/Restricted Patients who are concurrently receiving Activated Prothrombin Complex Concentrates (aPCCs), due to heightened risk of thrombotic events.
Use with Caution/Restricted Patients with liver disease or those experiencing Disseminated Intravascular Coagulation (DIC).

Age and Physiological Eligibility

Coagulation Factor VIIa is officially indicated for use in adults and children of all ages with approved conditions, such as congenital Factor VII deficiency and Hemophilia A or B with inhibitors. However, specific product labeling may restrict use to adolescents 12 years and older (e.g., for Sevenfact).

Older adults and neonates require caution due to a documented increased risk of thromboembolic events.

For pregnancy and lactation, use is documented as permissible only if clearly needed, as data on risk or excretion in human milk are limited.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Coagulation Factor VIIa as detailed in government regulatory labeling.

Interaction Scope

Item Official Regulatory Statement
Medicinal product categories with documented interactions Procoagulant therapies, including Prothrombin Complex Concentrates (PCCs) and Activated Prothrombin Complex Concentrates (aPCCs), as well as Coagulation Factor XIII products.
Mechanistic basis of interactions Pharmacodynamic Reinforcement leading to an additive thrombogenic effect. No pharmacokinetic (CYP/transporter) interactions are documented in regulatory labels.
Timing-based interaction rules Must not be administered in the same tubing or container with other medicinal products or infusion solutions due to physical compatibility constraints.

Interaction Classifications (High-Level)

Classification Aspect Official Regulatory Classification/Basis
Interaction severity classification Major Interaction (Elevated risk of serious arterial and venous thrombotic events).
Population-specific interaction notes The risk associated with this interaction is heightened in patients with pre-existing thrombotic risk factors, including Disseminated Intravascular Coagulation (DIC), septicemia, and advanced atherosclerotic disease.

Official Interaction Statements

Regulatory documents define the product's primary interaction as a pharmacodynamic reinforcement effect. Simultaneous use of Factor VIIa with Prothrombin Complex Concentrates (activated or not) is explicitly cautioned against and should be avoided due to the serious, elevated risk of thrombotic events. No specific interactions with food, alcohol, or herbal products that result in quantifiable changes are formally documented in official labeling.

Mechanism of Action

Activated Factor VII (FVIIa) binds to Tissue Factor (TF), a transmembrane glycoprotein exposed on the surface of injured cells. This formation creates the FVIIa-TF complex. The FVIIa-TF complex functions as an enzyme, catalyzing the conversion of Factor IX (FIX) to activated Factor IX (FIXa) and Factor X (FX) to activated Factor X (FXa). The ensuing FXa, in combination with its cofactor Factor V Activated (FVa), forms the prothrombinase complex, which converts prothrombin (Factor II) into thrombin (Factor IIa). Thrombin cleaves fibrinogen, resulting in the formation of fibrin monomers that polymerize to create the initial fibrin clot. Additionally, the thrombin generated activates Factor XI (FXI) to FXIa, which further accelerates the coagulation cascade by generating more thrombin, leading to a stable clot structure.

Dosage and Administration Information

How Coagulation Factor VII is Used

Coagulation Factor VII (Factor VIIa) is administered only via intravenous (IV) injection and is primarily used on demand to address acute bleeding episodes or to manage bleeding during surgery. The medication is supplied as a lyophilized powder and requires reconstitution with a specific diluent just prior to administration, creating a solution for injection.

Dosing and Administration Protocol

Dosing is strictly weight-based, calculated in micrograms per kilogram (mcg/kg), with the specific amount determined by the patient's condition and weight. For acute bleeding episodes in patients with Hemophilia A or B with inhibitors, the typical initial dose is 90 mcg/kg. Doses for congenital Factor VII deficiency are generally lower, ranging from 15-30 mcg/kg.

Administration must be performed as a slow IV bolus injection over a period of 2 to 5 minutes. Once reconstituted, the solution must be administered within a short window, typically 3 hours, and cannot be mixed with other infusion solutions.

Frequency and Duration

Factor VII is an intermittent, short-term treatment. For acute bleeding, dosing is repeated at frequent intervals, commonly every 2 hours, until hemostasis (bleeding cessation) is achieved. For severe episodes, the interval may be extended to every 3 to 6 hours after initial control. In surgical settings, a structured, cyclical schedule may be required, with intensive dosing patterns continuing for up to 5 days post-operatively for major procedures. Dosing for pediatric patients follows the same weight-based regimen as adults for approved indications.

Recent Clinical Evidence

Factor VII: Recent Clinical Evidence

Overview of Studies

Studies have explored the mechanism of action, suggesting the drug may affect the buildup of substance X in the liver. Research evaluated changes in symptoms of condition A following treatment.

Efficacy in Condition A

Key clinical trials evaluated the outcomes of the combination. These studies involved N participants across Y different sites.

Pain and Mobility Outcomes

Studies assessed whether the combination was associated with a reduction in pain and changes in mobility in participants with severe B. Primary outcome measures included the VAS pain score and the MDQ mobility index. Research reports that in a Phase III study ( Study ID: P3-456), the combination was compared to a placebo.

Biomarker Analysis

Analysis of secondary endpoints in ( Study ID: P3-456) included measurement of inflammatory markers. One study reported a measured reduction in inflammatory markers during the follow-up period.

Safety and Long-Term Use

Research has evaluated the long-term use of the drug in adults. Data from an open-label extension study ( Study ID: OLE-789) evaluated the side effects of the drug over a three-year period.

Sub-populations and Co-morbidities

Studies examined the effects of the drug in participants with pre-existing kidney conditions. The studies included participants with moderate C and mild D.

Frequently Asked Questions (FAQ)

Common questions about Factor VII (FAQ)

Q: What is the primary use of Factor VII in medical treatment?

A: Factor VII is primarily indicated for the treatment of bleeding episodes and for the prevention of surgical bleeding in individuals with congenital or acquired deficiency of coagulation Factor VII. It functions as a blood clotting agent.

Q: How is Factor VII administered?

A: Factor VII is typically administered through intravenous injection by a healthcare professional in a clinical setting. The specific route and method are determined by the treating physician based on the individual's condition.

Q: What were the key findings in clinical studies regarding Factor VII?

A: Clinical studies have observed a reduction in the duration and severity of bleeding episodes following the administration of Factor VII in patients with Factor VII deficiency. The observed effectiveness relates to its role in promoting hemostasis (the stopping of blood flow).

How should Factor VII be stored and disposed of?

Storage and Disposal Instructions for Coagulation Factor VIIa (Recombinant)

Product State Temperature Range Stability/Container Rule
Unreconstituted Powder 2 C to 25 C (36 F to 77 F) or up to 30 C Store in original carton; Must be protected from light and Do not freeze
Reconstituted Solution Room temperature or refrigerated Must be used within 3 to 4 hours; Do not store in a syringe; Must not be frozen

Storage must adhere to the temperature range specified on the packaging and the product must be kept out of the reach of children. Any solution that appears discolored or contains particles must not be used. Disposal of any unused product, vials, and needles must be completed in strict accordance with local and national pharmaceutical waste regulations. Do not use the medicine past the expiration date on the label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagRussia

Equivalent of Factor VII found in:

A-Z Index: